Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Commentary

Latent autoimmune diabetes in adults (LADA)—more than a name

Authors: L. Groop, T. Tuomi, M. Rowley, P. Zimmet, I. R. Mackay

Published in: Diabetologia | Issue 9/2006

Login to get access

Excerpt

In a recent editorial [1], Edwin Gale questioned the rationale for the designation of latent autoimmune diabetes in adults (LADA) [2] as a distinct aetiological entity. The reasons given for this were that measurements of antibodies to GAD are imprecise and cut-off levels are arbitrary, and that the clinical value of a diagnosis of LADA has not been demonstrated. We, however, think that there are persuasive reasons for retention of LADA as a subgroup of diabetes. …
Literature
1.
Gale EAM (2005) Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 48:2195–2199PubMedCrossRef
2.
Tuomi T, Groop L, Zimmet P, Rowley M, Mackay I (1993) Antibodies to glutamic acid decarboxylase (GAD) reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMedCrossRef
3.
Groop L, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 35:237–241PubMedCrossRef
4.
Groop L, Eriksson J, Ekstrand A et al (1991) Metabolic characteristics of autoimmune diabetes in adults. Diabetologia 34:46–51PubMedCrossRef
5.
Fourlanos S, Dotta F, Greenbaum CJ et al (2005) Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206–2212PubMedCrossRef
6.
Tuomi T, Carlsson ÅL, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMedCrossRef
7.
Dawkins RL (1985) Sensitivity and specificity of antibody testing. In: Rose NR, Mackay IR (eds) The autoimmune diseases. Academic, San Diego, pp 669–693
8.
Mackay IR, Burnet FM (1963) Autoimmunity in thyroid disease. In: Autoimmune diseases. Pathogenesis, chemistry and therapy. Thomas, Springfield, pp 47–68
9.
Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM (2005) Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 54(Suppl 2):S62–S67PubMedCrossRef
10.
Davis TME, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702PubMedCrossRef
11.
Scadding JG (1996) Essentialism and nominalism in medicine: logic of diagnosis in disease terminology. Lancet 348:594–596PubMedCrossRef
12.
Groop L, Miettinen A, Groop P-H et al (1988) Organ-specific autoimmunity and HLA-DR antigens as markers for β-cell destruction in patients with type II diabetes. Diabetes 37:99–103PubMedCrossRef
13.
Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef
14.
Florez JC, Burtt N, de Bakker PI et al (2004) Haplotype structure and genotype–phenotype correlations of the sulfonyulrea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53:1360–1368PubMedCrossRef
15.
Grant SF, Thorleifsson, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
16.
Borg H, Gottsäter A, Fernlund P, Sundkvist G (1994) A 12-year prospective of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult onset diabetes. Diabetes 51:1754–1762CrossRef
17.
Tripathy D, Carlsson ÅL, Lehto M et al (2000) Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43:1476–1483PubMedCrossRef
18.
Isomaa B, Almgren P, Henricsson M et al (1999) Chronic complications in patients with slowly progressing type 1 diabetes (LADA). Diabetes Care 22:1347–1353PubMedCrossRef
19.
Agardh CD, Cilio CM, Lethagen ÅL et al (2005) Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238–246PubMedCrossRef
Metadata
Title
Latent autoimmune diabetes in adults (LADA)—more than a name
Authors
L. Groop
T. Tuomi
M. Rowley
P. Zimmet
I. R. Mackay
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0345-x

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Article

The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study

Article

Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice

Article

Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n−3 polyunsaturated fatty acids

Article

Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus

Article

Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes

Article

Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits